Skip to main content
Erschienen in: Herz 2/2017

30.06.2016 | Original articles

Timing and long-term prognosis of recurrent MI after primary angioplasty

Stent thrombosis vs. non-stent-related reinfarction

verfasst von: A. Viveiros Monteiro, MD, R. Ramos, A. Fiarresga, L. de Sousa, D. Cacela, L. Patrício, L. Bernardes, C. Soares, R. Cruz Ferreira

Erschienen in: Herz | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

In patients recovering from an ST-segment elevation myocardial infarction (STEMI), it is not clear whether the negative impact of stent thrombosis (ST) is different from a non-stent-related recurrent myocardial infarction (NSRMI). This study sought to assess the long-term incidence and prognostic impact of recurrent myocardial infarction (MI) after percutaneous coronary intervention (PCI) for STEMI by comparing outcomes of ST versus NSRMI.

Patients and methods

From 2001 to 2007, 1025 patients undergoing PCI for STEMI were prospectively followed up. Patients with ST, with NSRMI, and those free from recurrent MI were compared regarding mortality and major adverse cardiac and cerebrovascular events (MACCE).

Results

Recurrent MI decreased from 37 events per 1000 person/months in the first month to 3.3 events per 1000 person/months after the first year. The cumulative 5‑year incidence of ST and NSRMI was 5.27 % and 13.2 %, respectively. MACCE at 60 months after recurrence were not significantly different for patients with reinfarction but were significantly higher than for patients free from any recurrent MI (both log-rank p < 0.001). However, the cumulative all-cause death rate did not differ between the three groups (27.8 vs. 26.7 vs. 23.0 %). Compared with ST occurring in the first 30 days after PCI for STEMI, early NSRMI was associated with a significantly reduced risk for all-cause death (HR, 0.21; 95 % CI, 0.33–3.30) but this association did not persist for recurrent MIs occurring in the late (HR, 1.05; 95 % CI, 0.33–3.30) or very late follow-up periods.

Conclusion

Although ST was associated with a significant increase in adverse events in the early recovery period, in the long term, MACCE and all-cause mortality rates were comparable to those for NSRMI.
Literatur
1.
Zurück zum Zitat Buch P, Rasmussen S, Gislason GH et al (2007) Temporal decline in the prognostic impact of a recurrent acute myocardial infarction 1985 to 2002. Heart 93:210–215CrossRefPubMed Buch P, Rasmussen S, Gislason GH et al (2007) Temporal decline in the prognostic impact of a recurrent acute myocardial infarction 1985 to 2002. Heart 93:210–215CrossRefPubMed
2.
Zurück zum Zitat Fox KA, Steg PG, Eagle KA et al (2007) Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 297:1892–1900CrossRefPubMed Fox KA, Steg PG, Eagle KA et al (2007) Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 297:1892–1900CrossRefPubMed
3.
Zurück zum Zitat Steg PG, James SK, Atar D et al (2012) ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The task force on the management of ST-segment elevation acute myocardial infarction of the european society of cardiology (ESC). Eur Heart J 33:2569–2619CrossRefPubMed Steg PG, James SK, Atar D et al (2012) ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The task force on the management of ST-segment elevation acute myocardial infarction of the european society of cardiology (ESC). Eur Heart J 33:2569–2619CrossRefPubMed
4.
Zurück zum Zitat De Luca G, Suryapranata H, Stone GW et al (2008) Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. Int J Cardiol 126:37–44CrossRefPubMed De Luca G, Suryapranata H, Stone GW et al (2008) Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. Int J Cardiol 126:37–44CrossRefPubMed
5.
Zurück zum Zitat Kikkert W, Hoebers L, Damman P et al (2014) Recurrent myocardial infarction after primary Percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am J Cardiol 113:229–235CrossRefPubMed Kikkert W, Hoebers L, Damman P et al (2014) Recurrent myocardial infarction after primary Percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am J Cardiol 113:229–235CrossRefPubMed
6.
Zurück zum Zitat Miyamoto T, Ishikawa T, Nakano Y, Mutoh M (2016) Very long-term clinical and angiographic outcomes after sirolimus- and paclitaxel-eluting stent placement for ST-elevation myocardial infarction: a propensity score-matched comparison. Cardiovasc Interv Ther. doi:10.1007/s12928-016-0390-4PubMed Miyamoto T, Ishikawa T, Nakano Y, Mutoh M (2016) Very long-term clinical and angiographic outcomes after sirolimus- and paclitaxel-eluting stent placement for ST-elevation myocardial infarction: a propensity score-matched comparison. Cardiovasc Interv Ther. doi:10.1007/s12928-016-0390-4PubMed
7.
Zurück zum Zitat Aoki J, Lansky AJ, Mehran R, Moses J, Bertrand ME, McLaurin BT (2009) Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: The acute Catheterization and urgent intervention triage strategy trial. Circulation 119:687–698CrossRefPubMed Aoki J, Lansky AJ, Mehran R, Moses J, Bertrand ME, McLaurin BT (2009) Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: The acute Catheterization and urgent intervention triage strategy trial. Circulation 119:687–698CrossRefPubMed
8.
Zurück zum Zitat Chechi T, Vecchio S, Vittori G et al (2008) ST-segment elevation myocardial infarction due to early and late Stent thrombosis A new group of high-risk patients. JACC 51:2396–2402CrossRefPubMed Chechi T, Vecchio S, Vittori G et al (2008) ST-segment elevation myocardial infarction due to early and late Stent thrombosis A new group of high-risk patients. JACC 51:2396–2402CrossRefPubMed
9.
Zurück zum Zitat Kubo S, Kadota K, Ichinohe T et al (2013) Comparison of long-term outcome after Percutaneous coronary intervention for Stent thrombosis between early, late, and very late Stent thrombosis. Circ J 78:101–109PubMed Kubo S, Kadota K, Ichinohe T et al (2013) Comparison of long-term outcome after Percutaneous coronary intervention for Stent thrombosis between early, late, and very late Stent thrombosis. Circ J 78:101–109PubMed
10.
Zurück zum Zitat Kimura T, Morimoto T, Kozuma K, Honda Y, Kume T, Aizawa T (2010) Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation 122:52–61CrossRefPubMed Kimura T, Morimoto T, Kozuma K, Honda Y, Kume T, Aizawa T (2010) Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation 122:52–61CrossRefPubMed
11.
Zurück zum Zitat Hochman JS, Sleeper LA, Godfrey E, McKinlay SM, Sanborn T, Col J, LeJemtel T (1999) Should we emergently revascularize occluded coronaries for cardiogenic shocK: an international randomized trial of emergency PTCA/CABG-trial design. the SHOCK trial study group. Am Heart J 137:313–321CrossRefPubMed Hochman JS, Sleeper LA, Godfrey E, McKinlay SM, Sanborn T, Col J, LeJemtel T (1999) Should we emergently revascularize occluded coronaries for cardiogenic shocK: an international randomized trial of emergency PTCA/CABG-trial design. the SHOCK trial study group. Am Heart J 137:313–321CrossRefPubMed
12.
Zurück zum Zitat Thygesen K, Alpert JS, Jaffe AS et al (2012) Third universal definition of myocardial infarction. Eur Heart J 33:2551–2567CrossRefPubMed Thygesen K, Alpert JS, Jaffe AS et al (2012) Third universal definition of myocardial infarction. Eur Heart J 33:2551–2567CrossRefPubMed
13.
Zurück zum Zitat Cutlip DE, Windecker S, Mehran R et al (2007) Clinical endpoints in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351CrossRefPubMed Cutlip DE, Windecker S, Mehran R et al (2007) Clinical endpoints in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351CrossRefPubMed
14.
Zurück zum Zitat Yan BP, Duffy SJ, Clark DJ et al (2008) Rates of Stent thrombosis in bare-metal versus drug-Eluting Stents (from a large australian Multicenter registry). Am J Cardiol 101:1716–1722CrossRefPubMed Yan BP, Duffy SJ, Clark DJ et al (2008) Rates of Stent thrombosis in bare-metal versus drug-Eluting Stents (from a large australian Multicenter registry). Am J Cardiol 101:1716–1722CrossRefPubMed
15.
Zurück zum Zitat Thune JJ, Signorovitch JE, Kober L et al (2011) Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. Eur J Heart Fail 13:148–153CrossRefPubMed Thune JJ, Signorovitch JE, Kober L et al (2011) Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. Eur J Heart Fail 13:148–153CrossRefPubMed
16.
Zurück zum Zitat De la Torre-Hernandez JM, Alfonso F, Hernandez F, Elizaga J, Sanmartin M, Pinar E (2008) Drug-eluting stent thrombosis: Results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 51:986–990CrossRefPubMed De la Torre-Hernandez JM, Alfonso F, Hernandez F, Elizaga J, Sanmartin M, Pinar E (2008) Drug-eluting stent thrombosis: Results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 51:986–990CrossRefPubMed
17.
Zurück zum Zitat Wenaweser P, Daemen J, Zwahlen M, Van Domburg R, Juni P, Vaina S (2008) Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4‑year results from a large 2‑institutional cohort study. J Am Coll Cardiol 52:1134–1140CrossRefPubMed Wenaweser P, Daemen J, Zwahlen M, Van Domburg R, Juni P, Vaina S (2008) Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4‑year results from a large 2‑institutional cohort study. J Am Coll Cardiol 52:1134–1140CrossRefPubMed
18.
Zurück zum Zitat Kubo S, Kadota K, Ozaki M, Ichinohe T, Eguchi H, Miyake K (2013) Difference in clinical and angiographic characteristics of very late stent thrombosis between drug-eluting and bare-metal stent implantations. Circ J 77:1453–1460CrossRefPubMed Kubo S, Kadota K, Ozaki M, Ichinohe T, Eguchi H, Miyake K (2013) Difference in clinical and angiographic characteristics of very late stent thrombosis between drug-eluting and bare-metal stent implantations. Circ J 77:1453–1460CrossRefPubMed
19.
Zurück zum Zitat Stone GW, Witzenbichler B, Guagliumi G et al (2011) Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3‑year results from a multicentre, randomised controlled trial. Lancet 377:2193–2204CrossRefPubMed Stone GW, Witzenbichler B, Guagliumi G et al (2011) Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3‑year results from a multicentre, randomised controlled trial. Lancet 377:2193–2204CrossRefPubMed
20.
Zurück zum Zitat Vink MA, Dirksen MT, Suttorp MJ et al (2011) A follow-up study of the PASSION (Paclitaxel-Eluting versus conventional Stent in myocardial infarction with ST-segment elevation) trial. J Am Coll Cardiol Intv 4:24–29CrossRef Vink MA, Dirksen MT, Suttorp MJ et al (2011) A follow-up study of the PASSION (Paclitaxel-Eluting versus conventional Stent in myocardial infarction with ST-segment elevation) trial. J Am Coll Cardiol Intv 4:24–29CrossRef
21.
Zurück zum Zitat Spaulding C, Teiger E, Commeau P et al (2011) Four-year follow-up of TYPHOON (trial to assess the use of the CYPher Sirolimus-Eluting coronary Stent in acute myocardial infarction treated with ballOON Angioplasty). J Am Coll Cardiol Intv 4:14–23CrossRef Spaulding C, Teiger E, Commeau P et al (2011) Four-year follow-up of TYPHOON (trial to assess the use of the CYPher Sirolimus-Eluting coronary Stent in acute myocardial infarction treated with ballOON Angioplasty). J Am Coll Cardiol Intv 4:14–23CrossRef
22.
Zurück zum Zitat Boden H, Van der Hoeven BL, Liem S et al (2012) Five-year clinical follow-up from the MISSION! Intervention Study: sirolimus-eluting stent versus bare metal stent implantation in patients with ST-segment elevation myocardial infarction, a randomised controlled trial. EuroIntervention 7:1021–1029CrossRefPubMed Boden H, Van der Hoeven BL, Liem S et al (2012) Five-year clinical follow-up from the MISSION! Intervention Study: sirolimus-eluting stent versus bare metal stent implantation in patients with ST-segment elevation myocardial infarction, a randomised controlled trial. EuroIntervention 7:1021–1029CrossRefPubMed
23.
Zurück zum Zitat Valgimigli M, Campo G, Gambetti S et al (2013) Three-year follow-up of the MULTIcentre evaluation of single high-dose bolus tiRofiban versus Abciximab with Sirolimus-eluting STEnt or bare-metal Stent in acute myocardial infarction studY (MULTISTRATEGY). Int J Cardiol 165:134–141CrossRefPubMed Valgimigli M, Campo G, Gambetti S et al (2013) Three-year follow-up of the MULTIcentre evaluation of single high-dose bolus tiRofiban versus Abciximab with Sirolimus-eluting STEnt or bare-metal Stent in acute myocardial infarction studY (MULTISTRATEGY). Int J Cardiol 165:134–141CrossRefPubMed
24.
Zurück zum Zitat Holmvang L, Kelbæk H, Kaltoft A et al (2013) Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST segment elevationmyocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction). JACC Cardiovasc Interv 6:548–553CrossRefPubMed Holmvang L, Kelbæk H, Kaltoft A et al (2013) Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST segment elevationmyocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction). JACC Cardiovasc Interv 6:548–553CrossRefPubMed
25.
Zurück zum Zitat Park KW, Kang SH, Chung WY et al (2010) “Real world” comparison of drug-eluting stents vs bare metal stents in the treatment of unselected patients with acute ST-segment elevation myocardial infarction. Circ J 74:1111–1120CrossRefPubMed Park KW, Kang SH, Chung WY et al (2010) “Real world” comparison of drug-eluting stents vs bare metal stents in the treatment of unselected patients with acute ST-segment elevation myocardial infarction. Circ J 74:1111–1120CrossRefPubMed
26.
Zurück zum Zitat Brodie B, Pokharel Y, Fleishman N et al (2011) Very late Stent thrombosis after primary Percutaneous coronary intervention with bare-metal and drug-Eluting Stents for ST-segment elevation myocardial infarction A 15-year single-center experience. J Am Coll Cardiol Intv 4:30–38CrossRef Brodie B, Pokharel Y, Fleishman N et al (2011) Very late Stent thrombosis after primary Percutaneous coronary intervention with bare-metal and drug-Eluting Stents for ST-segment elevation myocardial infarction A 15-year single-center experience. J Am Coll Cardiol Intv 4:30–38CrossRef
27.
Zurück zum Zitat Sattur S, Orshaw P, Boura J, Harjai KJ (2012) Long-term safety and effectiveness of drug-eluting stents compared to bare metal stents in ST elevationmyocardial infarction: findings from the Guthrie Health Off-label Stent (GHOST) Registry. J Interv Cardiol 25:118–125CrossRefPubMed Sattur S, Orshaw P, Boura J, Harjai KJ (2012) Long-term safety and effectiveness of drug-eluting stents compared to bare metal stents in ST elevationmyocardial infarction: findings from the Guthrie Health Off-label Stent (GHOST) Registry. J Interv Cardiol 25:118–125CrossRefPubMed
28.
Zurück zum Zitat Simsek C, Magro M, Boersma E et al (2011) Comparison of six-year clinical outcome of Sirolimus- and Paclitaxel-Eluting Stents to bare-metal Stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH and T‑SEARCH registries. J Invasive Cardiol 23:336–341PubMed Simsek C, Magro M, Boersma E et al (2011) Comparison of six-year clinical outcome of Sirolimus- and Paclitaxel-Eluting Stents to bare-metal Stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH and T‑SEARCH registries. J Invasive Cardiol 23:336–341PubMed
29.
Zurück zum Zitat Polonski L, Gasior M, Gierlotka M et al (2011) A comparison of ST elevation versus non-ST elevation myocardial infarction outcomes in a large registry database: are non-ST myocardial infarctions associated with worse long-term prognoses? Int J Cardiol 152:70–77CrossRefPubMed Polonski L, Gasior M, Gierlotka M et al (2011) A comparison of ST elevation versus non-ST elevation myocardial infarction outcomes in a large registry database: are non-ST myocardial infarctions associated with worse long-term prognoses? Int J Cardiol 152:70–77CrossRefPubMed
30.
Zurück zum Zitat Velders MA, Boden H, Hoeven B et al (2013) Long-term outcome of second-generation everolimus-eluting stents and Endeavor zotarolimus-eluting stents in a prospective registry of ST-elevation myocardial infarction patients. EuroIntervention 8:1199–1206CrossRefPubMed Velders MA, Boden H, Hoeven B et al (2013) Long-term outcome of second-generation everolimus-eluting stents and Endeavor zotarolimus-eluting stents in a prospective registry of ST-elevation myocardial infarction patients. EuroIntervention 8:1199–1206CrossRefPubMed
31.
Zurück zum Zitat Pedersen F, Butrymovich V, Kelbæk H (2014) Short- and long-term cause of death in patients treated with primary PCI for STEMI. J Am Coll Cardiol 64:2101–2108CrossRefPubMed Pedersen F, Butrymovich V, Kelbæk H (2014) Short- and long-term cause of death in patients treated with primary PCI for STEMI. J Am Coll Cardiol 64:2101–2108CrossRefPubMed
32.
Zurück zum Zitat Mega J, Braunwald E, Murphy SA et al (2013) Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-Thrombolysis in myocardial infarction-51). J Am Coll Cardiol 61:1853–1859CrossRefPubMed Mega J, Braunwald E, Murphy SA et al (2013) Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-Thrombolysis in myocardial infarction-51). J Am Coll Cardiol 61:1853–1859CrossRefPubMed
33.
Zurück zum Zitat Nidorf MS, Eikelboom J, Budgeon C, Thompson PL (2013) Low-dose Colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 61:404–410CrossRefPubMed Nidorf MS, Eikelboom J, Budgeon C, Thompson PL (2013) Low-dose Colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 61:404–410CrossRefPubMed
Metadaten
Titel
Timing and long-term prognosis of recurrent MI after primary angioplasty
Stent thrombosis vs. non-stent-related reinfarction
verfasst von
A. Viveiros Monteiro, MD
R. Ramos
A. Fiarresga
L. de Sousa
D. Cacela
L. Patrício
L. Bernardes
C. Soares
R. Cruz Ferreira
Publikationsdatum
30.06.2016
Verlag
Springer Medizin
Erschienen in
Herz / Ausgabe 2/2017
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-016-4446-0

Weitere Artikel der Ausgabe 2/2017

Herz 2/2017 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.